secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001193125-23-175647
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics hosts SNS-101 KOL event; no new data disclosed
---------------------------------------------------------------------

- Virtual key opinion leader event on June 27, 2023, featuring SNS-101 for solid tumors.
- Presenters include CEO John Celebi, CSO Dr. Edward van der Horst, CMO Ron Weitzman.
- Guest speaker: Dr. James Gulley, Co-Director, Center for Immuno-Oncology at NCI.
- Event is forward-looking; no clinical results or financial guidance provided.
- SNS-101 positioned as potential transformative treatment; no material milestones announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523175647/0001193125-23-175647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523175647/d505713d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-175647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer